Decitabine
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia
Trial Timeline
Aug 1, 2006 → May 1, 2012
NCT ID
NCT00398983About Decitabine
Decitabine is a phase 2/3 stage product being developed by Eisai for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00398983. Target conditions include Acute Myelogenous Leukemia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00538876 | Phase 1 | Completed |
| NCT00477386 | Phase 1/2 | Completed |
| NCT00398983 | Phase 2/3 | Completed |
| NCT00349596 | Phase 1 | Completed |
| NCT00760084 | Phase 2 | Completed |
| NCT00260065 | Phase 2 | Completed |
| NCT00358644 | Phase 2 | Completed |
| NCT00113321 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Myelogenous Leukemia